| Literature DB >> 33987216 |
Emily Ouma1, Michel Dione2, Nadhem Mtimet3, Peter Lule1, Angie Colston4, Samuel Adediran4,5, Delia Grace6,7.
Abstract
Taenia solium cysticercosis disease remains a key challenge to the pig sector in low- and middle-income countries in sub-Saharan Africa, Latin America and South East Asia, resulting in both economic losses and public health impacts. The World Health Organization has ranked it first on the global scale of foodborne parasites. A One Health approach has been recommended for reduction of infection pressure and eradication in the longer term. A new vaccine TSOL18 (Cysvax™), applied in combination with oxfendazole (Paranthic 10%™), a dewormer drug has been developed and field tested for the control of T. solium cysticercosis, with high potential to break the disease cycle. It is however unclear whether the products can be marketed through a market driven approach, and if smallholder pig farmers would be willing to take up and pay for the vaccine-oxfendazole combination. A choice experiment methodology was used to assess the potential demand and willingness to pay for the vaccine-oxfendazole combination by Ugandan smallholder pig farmers, and demand for vaccinated pigs by pig traders. The results showed that farmers highly valued quality assurance attributes and were not keen on the vaccine if there were no associated returns in the form of premium price for vaccinated pigs during sales. They were willing to pay US$ 2.31 for the vaccine if it resulted in a premium price for vaccinated pigs. Furthermore, they preferred an accompanying vaccine viability detector as part of its quality assurance. The pig traders on the other hand preferred high carcass weight of pigs, potentially achieved by using oxfendazole. The results show that unless the pig market systems pay a premium price for vaccinated pigs, and quality assurance systems guarantee quality vaccine, uptake of the TSOL18 vaccine and oxfendazole by farmers through market mechanisms may be unsuccessful. The current pig marketing system does not reward food safety, the focus is mainly on carcass weight. Alternative delivery mechanisms for the vaccine through a mix of private-public investments needs to be explored, as the benefits of vaccinated pigs are societal and include reduction and elimination of neurocysticercosis in the long run.Entities:
Keywords: T. solium cysticercosis; TSOL18 vaccine-oxfendazole; Uganda; choice experiments; pigs
Year: 2021 PMID: 33987216 PMCID: PMC8110731 DOI: 10.3389/fvets.2021.611166
Source DB: PubMed Journal: Front Vet Sci ISSN: 2297-1769
TSOL18 vaccine and oxfendazole attributes.
| A. Cost of vaccine which includes the cost of two doses of oxfendazole and TSOL18 vaccine | 0. UGX10,500 (US$2.9) |
| B. Administration of vaccine which includes service fee for the veterinarian/animal health worker without including transport) | 0. UGX2,500 (US$0.7) per pig—service fee for veterinarian or animal health worker who administers vaccine and deworming service to a group of 10 farmers |
| 1. UGX4,000 (US$1.1) per pig—service fee for an animal health worker who administers vaccine and deworming service to one farmer | |
| 2. UGX6,000 (US$1.7) per pig—service fee for veterinarian who administers vaccine and dewormer to one farmer | |
| C.Improved pig weight gain | 0. Pig gains an extra 10% weight because other worms are killed by the dewormer |
| 1. Pig gains an extra 5% weight because other worms are killed by the dewormer | |
| D. Top up price premium for vaccinated pigs | 0. 50% of market price |
| E. Frequency of vaccination to attain immunity | 0. Once at 2 months old |
| 1. Twice (one dose at 2 months old and another dose 3 months after) | |
| 2. Three times (one dose at 2 months of age, second dose 3 months later, and a third dose after another 3 months) | |
| F. Vaccine viability detector | 0. Non-inclusion of an indicator to test for vaccine viability |
| 1. Inclusion of indicator that shows vaccine viability |
Exchange rate: US$1 is equivalent to UGX 3600 during the study period.
Attributes for vaccinated pigs.
| A. Top-up premium price due to | 0. 5% top-up |
| B. Market price of pig (average of a 40-kilogram liveweight pig) | 0. UGX155,000 (US$43.1) |
| 1. UGX200,000 (US$55.6) | |
| 2. UGX225,000 (US$62.5) | |
| 3. UGX250,000 (US$69.4) | |
| C. Proof of vaccination | 0. Producer's word |
| 1. Certificate provided by a government veterinarian | |
| 2. Certificate provided by a private veterinarian | |
| 3. Vaccinated pigs are ear-tagged | |
| D. Improved carcass weight gain | 0. Pig gains an extra 15% carcass weight because other worms are killed by the dewormer |
| 1. Pig gains an extra 10% carcass weight because other worms are killed by the dewormer | |
| 2. Pig gains an extra 5% carcass weight because other worms are killed by the dewormer |
Exchange rate: US$1 is equivalent to UGX 3600 during the study period.
Figure 1An example of a choice set option for farmers.
Figure 2An example of a choice set option for traders.
Choice experiment variable coding.
| Cost of vaccine | Cost in US$ |
| Premium price | % top up of market price |
| Low vaccination frequency | 1 = Once at 2 months, 0 otherwise |
| Medium vaccination frequency | 1 = Twice in the life of the pig, 0 otherwise |
| High vaccination frequency | 1 = Thrice in the life of the pig, 0 otherwise |
| Weight gain | % of weight gain in the pig due to the dewormer |
| Vaccine viability detector | 1 = Inclusion of a vaccine viability detector, 0 otherwise |
| Vaccine administration cost | Cost in US$ |
| Market price of 40 kg liveweight pig | Price in US$ |
| Top-up premium price | % increase due to pig vaccination |
| Proof of vaccination—private vet certificate | 1 = Yes, 0 otherwise |
| Proof of vaccination—government certificate | 1 = Yes, 0 otherwise |
| Proof of vaccination—ear tagging | 1 = Yes, 0 otherwise |
| Proof of vaccination—producer's word | 1 = Yes, 0 otherwise |
| Improved carcass weight | % increase in carcass weight due to deworming |
used as the base scenario in the model.
Figure 3Location of the study sites.
Pig traders' perceptions on practices and roles of various actors for control.
| I believe it is important to protect my consumers' health by ensuring that I sell | 9.1 | 0.0 | 0.0 | 30.0 | 60.6 |
| I condemn pork/pigs infected with | 3.0 | 0.0 | 0.0 | 24.2 | 72.7 |
| The market system should encourage farmers to vaccinate their pigs against | 3.0 | 0.0 | 6.1 | 69.7 | 21.2 |
| I believe the | 0.0 | 0.0 | 6.1 | 51.5 | 42.4 |
| I feel that control of | 3.0 | 12.1 | 3.0 | 39.4 | 42.4 |
| Public health is the role of the government, not the pig traders | 27.3 | 3.0 | 0.0 | 33.3 | 36.4 |
| I do not care about | 66.7 | 33.3 | 0.0 | 0.0 | 0.0 |
Mixed logit model estimates for T. solium cysticercosis vaccine attributes.
| Vaccine viability detector | 0.734*** | 0.113 |
| Vaccine administration cost | −0.255*** | 0.068 |
| Cost of vaccine | −1.230** | 0.525 |
| Constant | 2.627*** | 1.056 |
| Squared cost of vaccine | 0.000** | 0.000 |
| Premium price | 1.741*** | 0.209 |
| Low vaccination frequency | −0.156 | 0.110 |
| Medium vaccination frequency | −0.114 | 0.082 |
| Weight gain | −0.139 | 1.367 |
| Vaccine viability: Bukedea | −0.218 | 0.135 |
| Vaccine administration cost: Bukedea | 0.118** | 0.058 |
| Vaccine cost: Bukedea | 0.256*** | 0.051 |
| Vaccine viability detector | 1.549*** | 0.526 |
| Vaccine administration cost | 0.109 | 0.146 |
| Cost of vaccine | 0.243 | 0.152 |
| Likelihood ratio testa | 72.35 | |
| Log likelihood function at start values (MNL) | −2445.42 | |
| Simulated log likelihood function at convergence | −2212.38 | |
| Halton draws | 100 | |
| Number of observations | 1,764 | |
***, **, and * denotes p-values 1, 5, and 10%, respectively.
Coefficients of mixed logit random parameters, by district.
| Vaccine viability detector | 0.511 (0.015) | 0.727 (0.015) | −0.216*** |
| Cost of vaccine | −0.844 (0.001) | −1.098 (0.002) | 0.254*** |
| Vaccine administration cost | −0.118 (0.000) | −0.235 (0.001) | 0.117*** |
Standard error in parenthesis.
Denotes p-values at 1%.
Vaccine attribute implicit prices (willingness to pay values) in United States dollars (US$) and Uganda shillings (UGX).
| Vaccine viability detector | 0.495*** | 1,782 | 0.189 |
| Price premium | 1.173*** | 4,223 | 0.429 |
| Low vaccination frequency (once) | −0.105 | −378 | 0.084 |
| Medium vaccination frequency (twice) | −0.077 | −277 | 0.065 |
| Weight gain | −0.094 | −3,388 | 0.923 |
*** and ** denote significant variables at 1 and 5%, respectively.
T. solium vaccine attribute options selected by a high proportion of pig farmers.
| Cost of the vaccine (US$) | 5.00 | 2.92 | 2.92 |
| Vaccine administration cost per pig (US$) | 1.67 | 0.69 | 1.67 |
| Price premium (% of market price) | 15% | 50% | 50% |
| Vaccination frequency to attain immunity | Twice | Once | Once |
| Carcass weight gain (%) | 5% | 5% | 10% |
| Vaccine viability detector | None | None | Yes |
| % of farmers choosing the vaccine option | 14.9 | 37.4 | 48.9 |
Conditional logit estimates for T. solium cysticercosis vaccinated pigs.
| Purchase price of pig in USD | 0.040 | 0.0177 |
| Purchase price—squared | −0.000 | 0.000 |
| Percent of premium top up price due to vaccination | 1.847 | 1.384 |
| Improved % pig weight gain | 4.578 | 1.787 |
| Proof of vaccination—farmer's word | −0.194 | 0.218 |
| Proof of vaccination government veterinarian certification | −0.255 | 0.373 |
| Proof of vaccination private veterinarian certification | −0.079 | 0.210 |
| Log likelihood function | −349.469 | |
| Pseudo-R2 | 0.1154 | |
| Number of observations | 1,056 |
Base scenario for proof of vaccination—vaccinated pigs are ear tagged.
Denotes significant variables at 5%.